iDNA Vaccines to Generate Internal Virus Production

0
231

by Dr. Joseph Mercola, Mercola:

STORY AT-A-GLANCE
  • “Immunization DNA” or iDNA is a novel class of gene therapy “vaccines” that encodes for the whole virus
  • iDNA “vaccines” transcribe the full-length genomic RNA of the live-attenuated vaccine virus. The full-length viral RNA then initiates replication of live attenuated virus in the tissues of the vaccine recipient, resulting in an immune response

TRUTH LIVES on at https://sgtreport.tv/

  • The iDNA platform can be used to create vaccines in two different ways. You can either grow the iDNA in a culture to produce the vaccine in the conventional way, or you can inject the iDNA directly into the recipient and allow the body to produce the live attenuated virus internally
  • The first human trials for an iDNA shot that codes for a live virus could begin as early as 2024
  • In early April 2023, microbiologist Kevin McKernan reported he’d discovered DNA fragments in the mRNA shots made by Pfizer and Moderna, raising concerns about the possibility of genomic integration, autoimmune diseases and cancer. McKernan now reports having found a dose relationship between the load of DNA contamination and serious adverse events

If you thought mRNA injections were the craziest things the vaccine industry has cooked up lately, you haven’t seen the half of it yet. Up next, we have so-called “immunization DNA” or iDNA,1,2 a novel class of gene therapy “vaccines” that encodes for the whole virus.

It’s like mRNA, but on steroids. Rather than instructing your cells to produce a small portion, the spike protein of a given virus, iDNA products instruct cells to produce the virus in its entirety. As described in U.S. Patent 8691563B2:3

“The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses … When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient’s tissues.

This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.”

According to Taipei-based Medigen,4 which launched its iDNA “vaccine” platform in 2018, the technology “combines genetic stability of DNA with the exceptional efficacy of live attenuated vaccines.” “Live attenuated” vaccines refers to vaccines that contain live (viable) but weakened (less virulent) viruses.

The iDNA platform can be used to create vaccines in two different ways. You can either grow the iDNA in a culture to produce the vaccine in the conventional way, or you can inject the iDNA directly into the recipient and allow the body to produce the live attenuated virus internally.

What Could Go Wrong?

A 2016 paper described the iDNA process thus:5

“As any DNA vaccine, iDNA plasmids are isolated from bacteria and include a eukaryotic promoter, such as cytomegalovirus (CMV) major immediate-early promoter.

However, unlike a traditional DNA vaccine that involves transcription of mRNA for expression of a subunit antigen, the iDNA vaccines transcribe the full-length genomic RNA of the live-attenuated vaccine virus. The full-length viral RNA then initiates limited replication of live-attenuated virus in the tissues of vaccine recipient resulting in efficient immunization.

Essentially, the iDNA plasmid turns a limited number of cells in the vaccine recipient into the cell-scale factories for ‘manufacturing’ of live-attenuated vaccine.

Thus, the iDNA technology represents a novel type of DNA vaccine. With the introduction of DNA-launched iDNA vaccines, DNA-based vaccines can be subdivided into (i) DNA vaccines that express subunit antigens and (ii) DNA vaccines that launch replication-competent, live-attenuated vaccines …

Finally, the iDNA plasmid can be used as a genetically stable repository seed to prepare live-attenuated virus in vitro either for subsequent use as a traditional live-attenuated vaccine or, after virus inactivation, as a traditional inactivated virus vaccine.”

Oh joy. Considering the shocking harms mRNA injections are causing, which instruct your body to create just a small portion of a virus that has no capacity to self-replicate, what could conceivably happen if we start injecting DNA that causes your cells to churn out replication-competent live virus?

Different Product, Same Lies

Materials describing this technology claim the self-replication is restricted to “a limited number of cells in the vaccine recipient,” but where have we heard that before?

The mRNA shots were also supposed to stay in the vicinity of the injection site, causing just the cells in your deltoid to produce spike protein, but we now have proof it goes everywhere and cells throughout the body are producing the spike.

So, just how would an iDNA shot affect just “a small number of cells” when anything injected travels throughout the body? And how is the manufacturing turned off? They don’t say, which makes me think it’ll be just like the mRNA shots, which have no off switch and have been found to, in some people, produce spike protein for six months or more.

When your immune system is taxed with a chronic infection in this way, it begins to break down. Autoimmune diseases can also develop, which is what we’ve seen with the mRNA shots. The risk of iDNA causing symptomatic sickness also strikes me as significant, especially if your immune system is already weak.

‘DNA Vaccine’ Safety Is Unclear at Best

According to New Scientist,6 the first human trials for an iDNA shot that codes for a live virus could begin as early as 2024. Medigen is currently seeking approval to begin trials, but it’s unclear which infection is being targeted.

At present, no DNA vaccine has ever received full approval anywhere in the world. India did, however, issue emergency authorization for a DNA shot against COVID-19, called ZyCoV-D,7 which encoded for two viral proteins, the spike protein and an IgE signal peptide.8

In March 2023, Cochrane founder Peter Gøtzsche and investigative journalist Maryanne Demasi published a systematic review of papers that had data on serious adverse events (SAEs) associated with the COVID jabs. About ZyCoV-D, they wrote:9

“A trial in India of ZyCoV-D, a DNA-based vaccine, was also highly problematic. It randomized 27,703 patients, either aged 12-17 years or 60 years and older. A supplement reported one SAE [serious adverse event] in the vaccine group and none in the placebo group among the elderly and one vs two in ‘comorbid subjects.’

The main text was totally different, with no division as per randomized group. It described 15 SAEs, but seven of these were merely being COVID-19 positive, which is not an SAE and furthermore belongs to the reporting of the benefits, not the harms. There was one death in each group. This paper, which was difficult to interpret, was published in The Lancet.”10

An online search for data on ZyCoV-D left me empty handed, so aside from that Lancet paper (and an interim report on the same trial11), there doesn’t appear to be much out there.

As for what they used as the placebo is also anyone’s guess, as the paper doesn’t specify. Testing one vaccine against another is a simple trick to hide expected side effects, and we know that at least one other COVID shot (AstraZeneca), did not use an inert placebo but, rather, a vaccine against meningitis and septicemia.12,13

So, in summary, the safety of ZyCoV-D is anything but clear. Even if we did have data on it, it still would not tell us much about the safety of iDNA shots. ZyCoV-D only encodes for two proteins, whereas iDNA will encode an entire virus.

DNA in mRNA Shots Cause Concern Among Experts

In early April 2023, microbiologist Kevin McKernan reported he’d discovered DNA fragments in the mRNA shots made by Pfizer and Moderna.14,15,16,17 The highest level of DNA contamination found was 30%, meaning nearly one-third of the content of the shot was plasmid DNA. No DNA should be present in a commercial mRNA product that has been made under good manufacturing practices.

Since then, others have confirmed his results, including University of South Carolina professor Phillip Buckhaults. In September 2023, he testified18 to this before the South Carolina Senate Medical Affairs Ad-Hoc Committee on the Department of Health and Environmental Control (DHEC).

Read More @ Mercola.com